Upgrade to SI Premium - Free Trial

CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens on Pipeline Opportunity

September 28, 2026 4:30 AM
Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $80.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments